Unveiling Insights on BioMarin Pharmaceutical

By Kim Brooks • Tuesday, August 26 15:19 • Permanent Link

Large-cap Health Care company BioMarin Pharmaceutical has moved -2.2% so far today on a volume of 849,590, compared to its average of 2,248,434. In contrast, the S&P 500 index moved 0.0%.

BioMarin Pharmaceutical trades -41.36% away from its average analyst target price of $97.62 per share. The 26 analysts following the stock have set target prices ranging from $65.0 to $122.0, and on average have given BioMarin Pharmaceutical a rating of buy.

Anyone interested in buying BMRN should be aware of the facts below:

BioMarin Pharmaceutical's current price is 51.3% above its Graham number of $37.82, which implies that at its current valuation it does not offer a margin of safety
BioMarin Pharmaceutical has moved -35.3% over the last year, and the S&P 500 logged a change of 14.5%
Based on its trailing earnings per share of 3.39, BioMarin Pharmaceutical has a trailing 12 month Price to Earnings (P/E) ratio of 16.9 while the S&P 500 average is 29.3
BMRN has a forward P/E ratio of 19.1 based on its forward 12 month price to earnings (EPS) of $2.99 per share
Its Price to Book (P/B) ratio is 1.82 compared to its sector average of 3.19
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally.
Based in San Rafael, the company has 3,040 full time employees and a market cap of $10.99 Billion.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.